Acta Med. 2020, 63: 141-144

https://doi.org/10.14712/18059694.2020.33

Metachronous Isolated Contralateral Lung Metastasis from Pulmonary Adenosquamous Carcinoma with EGFR Mutation

Hitomi Kawaia, Kesato Iguchib, Norio Takayashikia, Shinichiro Okauchic, Hiroaki Satohc

aDivision of Pathology, Mito Medical Center, University of Tsukuba-Mito Medical Center, Mito, Ibaraki, Japan
bDivision of Surgery, Mito Medical Center, University of Tsukuba-Mito Medical Center, Mito, Ibaraki, Japan
cDivision of Respiratory Medicine, Mito Medical Center, University of Tsukuba-Mito Kyodo General Hospital, Mito, Ibaraki, Japan

Received June 4, 2019
Accepted June 20, 2020

References

1. Kondo N, Takuwa T, Hashimoto M, et al. Gene Mutation Analysis in determining late recurrence of adenocarcinoma of the lung. Ann Thorac Surg 2015; 100(2): 711–3. <https://doi.org/10.1016/j.athoracsur.2014.09.074>
2. Filosso PL, Ruffini E, Asioli S, et al. Adenosquamous lung carcinomas: a histologic subtype with poor prognosis. Lung Cancer 2011; 74(1): 25–9. <https://doi.org/10.1016/j.lungcan.2011.01.030>
3. Cooke DT, Nguyen DV, Yang Y, et al. Survival comparison of adenosquamous, squamous cell, and adenocarcinoma of the lung after lobectomy. Ann Thorac Surg 2010; 90(3): 943–8. <https://doi.org/10.1016/j.athoracsur.2010.05.025>
4. Miyazaki K, Ano T, Nakazawa K, et al. Late fatal recurrence in gefitinib- treated NSCLC patients. Tuberk Toraks 2007; 55(4): 400–3.
5. Kagohashi K, Nakayama H, Kagei K, et al. Thoracic radiotherapy for mediastinal nodal recurrence. Acta Medica (Hradec Kralove) 2009; 52(1): 23–5. <https://doi.org/10.14712/18059694.2016.103>
6. Jiang H. Overview of gefitinib in non-small cell lung cancer: an Asian perspective. Jpn J Clin Oncol 2009; 39(3): 137–50. <https://doi.org/10.1093/jjco/hyn139>
7. Armour AA, Watkins CL. The challenge of targeting EGFR: experience with gefitinib in nonsmall cell lung cancer. Eur Respir Rev 2010; 19(117): 186–96. <https://doi.org/10.1183/09059180.00005110> <PubMed>
8. Dungo RT, Keating GM. Afatinib: first global approval. Drugs 2013; 73(13): 1503–15. <https://doi.org/10.1007/s40265-013-0111-6>
9. Marchetti A, Martella C, Felicioni L, et al. EGFR mutations in nonsmall-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 2005; 23(4): 857–65. <https://doi.org/10.1200/JCO.2005.08.043>
10. Sugio K, Uramoto H, Ono K, et al. Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer 2006; 94(6): 896–903. <https://doi.org/10.1038/sj.bjc.6603040> <PubMed>
11. Tsao MS, Sakurada A, Ding K, et al. Prognostic and predictive value of epidermal growth factor receptor tyrosine kinase domain mutation status and gene copy number for adjuvant chemotherapy in nonsmall cell lung cancer. J Thorac Oncol 2011; 6(1): 139–47. <https://doi.org/10.1097/JTO.0b013e3181fd83a4> <PubMed>
12. Miyamae Y, Shimizu K, Hirato J, et al. Significance of epidermal growth factor receptor gene mutations in squamous cell lung carcinoma. Oncol Rep 2011; 25(4): 921–8.
13. Cancer Genome Atlas Research Network. Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012; 489(7417): 519–25.
14. Sato S, Nakamura M, Shimizu Y, et al. Impact of postoperative complications on outcomes of second surgery for second primary lung cancer. Surg Today 2020 Jun 1.
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive